Diamant Thaçi Selected Research

deucravacitinib

7/2022	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
2/2022	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
10/2018	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diamant Thaçi Research Topics

Disease

42	Psoriasis (Pustulosis Palmaris et Plantaris) 07/2022 - 08/2003
24	Atopic Dermatitis (Atopic Eczema) 05/2022 - 01/2003
9	Psoriatic Arthritis 01/2022 - 01/2006
9	Pruritus (Itching) 01/2021 - 11/2004
7	Eczema 01/2021 - 11/2004
6	Pain (Aches) 04/2022 - 11/2012
6	Infections 03/2022 - 07/2014
6	Skin Diseases (Skin Disease) 08/2021 - 08/2003
5	Neoplasms (Cancer) 03/2022 - 10/2006
3	Nasopharyngitis 01/2021 - 07/2014
3	Asthma (Bronchial Asthma) 01/2021 - 07/2014
3	Melanoma (Melanoma, Malignant) 10/2018 - 10/2006
2	Body Weight (Weight, Body) 06/2022 - 11/2012
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 01/2019
2	Bullous Pemphigoid (Pemphigoid) 01/2022 - 08/2021
2	Dermatitis 11/2021 - 01/2003
2	Inflammation (Inflammations) 09/2021 - 07/2014
2	Headache (Headaches) 01/2021 - 07/2014
2	Acne Vulgaris 01/2021 - 01/2021
2	Skin Neoplasms (Skin Cancer) 09/2015 - 01/2010
2	Drug-Related Side Effects and Adverse Reactions 03/2013 - 01/2006
1	Thrombocytopenia (Thrombopenia) 05/2022
1	Rheumatoid Arthritis 04/2022
1	Migraine Disorders (Migraine) 02/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Oral Candidiasis (Thrush) 01/2022
1	Ulcerative Colitis 11/2021
1	Rosacea (Acne Rosacea) 11/2021
1	Nausea 01/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021
1	Prurigo 06/2020
1	Discoid Lupus Erythematosus 04/2020
1	Kaposi Varicelliform Eruption (Eczema Herpeticum) 06/2019
1	Herpes Zoster 06/2019
1	Conjunctivitis 05/2019
1	Injection Site Reaction 05/2019
1	Autoimmune Diseases (Autoimmune Disease) 01/2019

Drug/Important Bio-Agent (IBA)

17	dupilumabIBA 05/2022 - 07/2014
9	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2020 - 06/2007
8	secukinumabIBA 06/2022 - 09/2015
7	calcipotriene (calcipotriol)FDA LinkGeneric 05/2021 - 01/2005
7	Adalimumab (Humira)FDA Link 01/2019 - 11/2012
6	Ustekinumab (CNTO 1275)FDA Link 05/2022 - 09/2015
6	Monoclonal AntibodiesIBA 06/2019 - 11/2012
5	betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric 05/2021 - 01/2006
5	pimecrolimus (Elidel)FDA Link 01/2010 - 01/2003
4	TYK2 Kinase (Tyrosine Kinase 2)IBA 07/2022 - 10/2018
4	InterleukinsIBA 06/2022 - 01/2016
4	Pharmaceutical PreparationsIBA 05/2022 - 03/2013
4	Janus Kinase InhibitorsIBA 11/2021 - 12/2016
4	Interleukin-13IBA 01/2021 - 07/2014
4	Calcineurin InhibitorsIBA 07/2014 - 06/2007
3	deucravacitinibIBA 07/2022 - 10/2018
3	apremilastIBA 07/2022 - 08/2017
3	Etanercept (Enbrel)FDA Link 04/2022 - 09/2015
3	ixekizumabIBA 02/2022 - 10/2018
3	Interleukin-4 (Interleukin 4)IBA 01/2021 - 07/2014
3	CytokinesIBA 01/2019 - 01/2003
2	guselkumabIBA 06/2022 - 02/2022
2	Immunoglobulin A (IgA)IBA 06/2022 - 01/2021
2	Certolizumab Pegol FDA Link 05/2022 - 08/2018
2	EnzymesIBA 05/2022 - 03/2013
2	Creatine Kinase (Creatine Phosphokinase)IBA 05/2022 - 01/2021
2	GlucocorticoidsIBA 04/2022 - 07/2014
2	risankizumabIBA 02/2022 - 01/2019
2	tildrakizumabIBA 02/2022 - 01/2017
2	Interleukin-23 (Interleukin 23)IBA 02/2022 - 01/2017
2	Biological ProductsIBA 02/2022 - 08/2018
2	abrocitinibIBA 01/2022 - 01/2021
2	Janus KinasesIBA 11/2021 - 01/2021
2	tofacitinibIBA 11/2021 - 12/2016
2	Janus Kinase 1IBA 01/2021 - 01/2020
2	upadacitinibIBA 01/2021 - 01/2020
2	Vitamin D FDA LinkGeneric 12/2020 - 09/2017
2	EsapentIBA 09/2017 - 09/2015
2	Prostaglandins AIBA 01/2017 - 01/2017
2	Methotrexate (Mexate)FDA LinkGeneric 01/2017 - 03/2016
2	Alitretinoin FDA Link 12/2016 - 11/2016
2	FumaratesIBA 05/2013 - 02/2011
2	Leflunomide (Arava)FDA LinkGeneric 03/2013 - 01/2006
2	Tacrolimus (Prograf)FDA LinkGeneric 09/2009 - 01/2005
2	Ointments (Pastes)IBA 01/2006 - 01/2005
1	brodalumabIBA 03/2022
1	Glucose (Dextrose)FDA LinkGeneric 02/2022
1	Interleukin-23 Subunit p19IBA 02/2022
1	Antirheumatic Agents (DMARD)IBA 01/2022
1	bimekizumabIBA 01/2022
1	Complement C5 (Complement 5)IBA 01/2022
1	Leukotriene B4IBA 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 09/2021
1	AutoantibodiesIBA 08/2021
1	pneumococcal purpura-producing principle (PPPP)IBA 01/2020
1	Immunologic Factors (Immunomodulators)IBA 06/2019
1	Tumor Necrosis FactorsIBA 06/2019
1	Interleukin-17 (Interleukin 17)IBA 01/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2018

Therapy/Procedure

20	Therapeutics 02/2022 - 08/2003
1	Phototherapy (Light Therapy) 01/2022
1	Duration of Therapy 12/2020